

Figure 1




Figure 2






Figure 3A




(SEQ ID NO: 1)

Figure 3B



ARC330 (SEQ ID NO: 2)

Figure 3C



ARC186 (SEQ ID NO: 4)

Figure 4




Figure 5




Figure 6





**standard PEGylation****multiple PEGylation****dimerization via PEGylation**

Figure 7A




Figure 7B

| ARC# | PEG modification                                              | IC50 (nM)     |
|------|---------------------------------------------------------------|---------------|
| 186  | No PEG                                                        | $0.5 \pm 0.1$ |
| 657  | ARC186+20 kDa                                                 | $0.6 \pm 0.1$ |
| 658  | ARC186+30 kDa                                                 | $0.5 \pm 0.1$ |
| 187  | 40 kDa branched 1,3 bis(mPEG-[20 kDa])-propyl-2-(4'-butamide) | $0.6 \pm 0.2$ |

Figure 7C




Figure 7D

| ARC# | PEG modification                                           | IC50 (nM)   |
|------|------------------------------------------------------------|-------------|
| 187  | 40K branched 1,3 bis(mPEG-[20 kDa])-propyl-2-(4'-butamide) | 0.38 ± 0.03 |
| 1537 | 40K Dow linear                                             | 0.39 ± 0.06 |
| 1730 | 2 x 20K linear                                             | 0.48 ± 0.04 |
| 1905 | 40K branched 2,3 bis(mPEG-[20 kDa])-propyl-1-carbamoyl     | 0.40 ± 0.03 |

Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20





Figure 21




Aptamer =

CmGfCfCGfCmGmGfU(CfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUf  
 UAfCfCfUmGfCmG-3T (SEQ ID NO 4)

ARC187 (SEQ ID NO: 5)

Figure 22



Aptamer =

CmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUf  
 UAfCfCfUmGfCmG-3T (SEQ ID NO 4)


ARC1905 (SEQ ID NO: 67)

Figure 23

| Group | # mice | Test Article                          | Dose      |                       | Measurements                                  |
|-------|--------|---------------------------------------|-----------|-----------------------|-----------------------------------------------|
|       |        |                                       | Conc (nM) | Perfusion rate mL/min |                                               |
| 1     | 5      | No aptamer                            | 0         | 3                     | Heart rate, rhythm, left ventricular pressure |
| 3     | 3      | Irrelevant aptamer at 50X molar ratio | 1500      | 3                     | Heart rate, rhythm, left ventricular pressure |
| 4     | 3      | ARC186 at molar equivalence           | 30        | 3                     | Heart rate, rhythm, left ventricular pressure |
| 5     | 5      | ARC186 at 10X molar ratio             | 300       | 3                     | Heart rate, rhythm, left ventricular pressure |
| 6     | 4      | ARC186 at 50X molar ratio             | 1500      | 3                     | Heart rate, rhythm, left ventricular pressure |

Figure 24

A



R

Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31

| Animal       | Treatment                        | Irrelevant | C3b | C5b-9 |
|--------------|----------------------------------|------------|-----|-------|
| 1-001 (1/26) | None                             | neg        | Pos | pos   |
| 1-002 (1-26) | None                             | neg        | Pos | pos   |
| 1-001        | None                             | neg        | Pos | pos   |
| 1-002        | None                             | neg        | Pos | pos   |
| 1-003        | None                             | neg        | Pos | pos   |
| 3-001        | Irrelevant aptamer 50X molar     | neg        | Pos | pos   |
| 3-002        | Irrelevant aptamer 50X molar     | neg        | Pos | pos   |
| 3-003        | Irrelevant aptamer 50X molar     | neg        | Pos | pos   |
| 4-001        | C5 aptamer molar equivalence     | neg        | Pos | pos   |
| 4-002        | C5 aptamer molar equivalence     | neg        | Pos | pos   |
| 4-003        | C5 aptamer molar equivalence     | neg        | Pos | pos   |
| 5-001        | C5 aptamer 10X molar equivalence | neg        | Pos | neg   |
| 5-002        | C5 aptamer 10X molar equivalence | neg        | Pos | neg   |
| 5-003        | C5 aptamer 10X molar equivalence | neg        | Pos | neg   |
| 5-004        | C5 aptamer 10X molar equivalence | neg        | Pos | neg   |
| 5-005        | C5 aptamer 10X molar equivalence | neg        | Pos | neg   |
| 6-001        | C5 aptamer 50X molar equivalence | neg        | Pos | neg   |
| 6-002        | C5 aptamer 50X molar equivalence | neg        | Pos | neg   |
| 6-003        | C5 aptamer 50X molar equivalence | neg        | Pos | neg   |
| 6-004        | C5 aptamer 50X molar equivalence | neg        | Pos | neg   |

Figure 32

| Animal | Compound | Serum   | Molar ratio | Increased EDP | Failure (Y or No) | Time to failure |
|--------|----------|---------|-------------|---------------|-------------------|-----------------|
| 1-001  | ARC658   | Human   | 0           | Y             | Y                 | 4 min 30 sec    |
| 1-002  | ARC658   | Human   | 0           | Y             | Y                 | 4 min 38 sec    |
| 1-003  | ARC658   | Human   | 0           | Y             | Y                 | 3 min 20 sec    |
| 1-004  | ARC658   | Human   | 0           | Y             | Y                 | 12 min 24 sec   |
| 1-005  | ARC658   | Human   | 0           | Y             | N                 | NA              |
| 1-006  | ARC658   | Human   | 0           | Y             | Y                 | 8 min 30 sec    |
| 1a-001 | ARC658   | Human   | 0.5         | Y             | Y                 | 7 min 22 sec    |
| 1a-002 | ARC658   | Human   | 0.5         | Y             | Y                 | 7 min 30 sec    |
| 1a-003 | ARC658   | Human   | 0.5         | Y             | Y                 | 8 min 13 sec    |
| 2-001  | ARC658   | Human   | 1           | N             | N                 | NA              |
| 2-002  | ARC658   | Human   | 1           | N             | N                 | NA              |
| 2-003  | ARC658   | Human   | 1           | N             | N                 | NA              |
| 2-004  | ARC658   | Human   | 1           | N             | N                 | NA              |
| 3-001  | ARC658   | Human   | 3           | N             | N                 | NA              |
| 3-002  | ARC658   | Human   | 3           | N             | N                 | NA              |
| 3-003  | ARC658   | Human   | 3           | N             | N                 | NA              |
| 6-001  | ARC658   | Primate | 0           | Y             | Y                 | 2 min 30 sec    |
| 6-002  | ARC658   | Primate | 0           | Y             | Y                 | 2 min 47 sec    |
| 6-003  | ARC658   | Primate | 0           | Y             | Y                 | 3 min 30 sec    |
| 6-004  | ARC658   | Primate | 0           | Y             | Y                 | 1 min 26 sec    |
| 6a-001 | ARC658   | Primate | 3           | Y             | Y                 | 5 min 2 sec     |
| 6a-002 | ARC658   | Primate | 3           | Y             | Y                 | 4 min 30 sec    |
| 6a-003 | ARC658   | Primate | 3           | Y             | Y                 | 3 min 43 sec    |
| 6a-004 | ARC658   | Primate | 3           | Y             | Y                 | 6 min 0 sec     |
| 7-001  | ARC658   | Primate | 10          | Y             | N                 | NA              |
| 7-002  | ARC658   | Primate | 10          | Y             | N                 | NA              |
| 7-003  | ARC658   | Primate | 10          | Y             | Y                 | 9 min 15 sec    |
| 7-004  | ARC658   | Primate | 10          | Y             | N                 | NA              |
| 9-001  | ARC658   | Primate | 20          | Y             | Y                 | 12 min 50 sec   |
| 11-001 | ARC658   | Primate | 30          | Y             | N                 | NA              |
| 11-002 | ARC658   | Primate | 30          | Y             | Y                 | 10 min 0 sec    |
| 11-003 | ARC658   | Primate | 30          | Y             | N                 | NA              |
| 13-001 | ARC658   | Primate | 60          | N             | N                 | NA              |
| 13-002 | ARC658   | Primate | 60          | N             | N                 | NA              |
| 13-003 | ARC658   | Primate | 60          | N             | N                 | NA              |

Figure 33




Figure 34

| Group Number | Number of Animals | Test Article         | Dosage Level (mg/kg) | Dose Volume (mL/kg) | Dosing Regimen             | Sample Collection                                |
|--------------|-------------------|----------------------|----------------------|---------------------|----------------------------|--------------------------------------------------|
| 1            | 3                 | ARC657<br>20 kDa PEG | 10                   | 1                   | Intravenous bolus on Day 1 | t= pre-dose, 0.5, 1, 2, 4, 8, 16, 24, 32, 48 hrs |
| 2            | 3                 | ARC658<br>30 kDa PEG | 10                   | 1                   | Intravenous bolus on Day 1 | t= pre-dose, 0.5, 1, 2, 4, 8, 16, 24, 32, 48 hrs |
| 3            | 3                 | ARC187<br>40 kDa PEG | 10                   | 1                   | Intravenous bolus on Day 1 | t= pre-dose, 0.5, 1, 2, 4, 8, 16, 24, 32, 48 hrs |

Figure 35

| PK of Anti-C5 Aptamer-PEG Conjugates In Sprague-Dawley Rat |         |         |         |         |         |         |
|------------------------------------------------------------|---------|---------|---------|---------|---------|---------|
| Aptamer                                                    | ARC657  |         | ARC658  |         | ARC187  |         |
| PEG Group                                                  | 20 kDa  |         | 30 kDa  |         | 40 kDa  |         |
|                                                            | MEAN    | STDEV   | MEAN    | STDEV   | MEAN    | STDEV   |
| time (hrs)                                                 | Cp (µM) | Cp (µM) | Cp (µM) | Cp (µM) | Cp (µM) | Cp (µM) |
| 0                                                          | 0.00    | 0.00    | 0.00    | 0.00    | 0.00    | 0.00    |
| 0.5                                                        | 12.77   | 2.67    | 2.97    | 0.62    | 6.52    | 1.77    |
| 1                                                          | 13.38   | 2.08    | 4.09    | 1.44    | 7.94    | 1.08    |
| 2                                                          | 6.63    | 1.87    | 3.40    | 0.66    | 6.57    | 1.56    |
| 4                                                          | 2.38    | 0.87    | 2.22    | 0.39    | 4.56    | 0.54    |
| 8                                                          | 0.72    | 0.18    | 2.87    | 1.84    | 1.53    | 0.57    |
| 12                                                         | 0.31    | 0.03    | 0.60    | 0.09    | 1.45    | 0.17    |
| 24                                                         | <LLOQ   | <LLOQ   | 0.47    | 0.17    | 0.73    | 0.03    |
| 32                                                         | <LLOQ   | <LLOQ   | <LLOQ   | <LLOQ   | 0.49    | 0.01    |
| 48                                                         | <LLOQ   | <LLOQ   | <LLOQ   | <LLOQ   | 0.27    | 0.02    |

Figure 36




Figure 37

| Species | Dose (mg/kg) | Admin Route | PEG Group | C <sub>max</sub> (µg/ml) | AUC <sub>0-24</sub> (µg·h/mL) | t <sub>1/2</sub> (α) (hr) | t <sub>1/2</sub> (β) (hr) | Cl <sub>CR</sub> (mL/min/kg) | V <sub>ss</sub> (mL/kg) |
|---------|--------------|-------------|-----------|--------------------------|-------------------------------|---------------------------|---------------------------|------------------------------|-------------------------|
| rat     | 10           | IV          | 20kD      | 169.97                   | 458                           | -                         | 2.05                      | 0.36                         | 65                      |
| rat     | 10           | IV          | 30kD      | 52.00                    | 497                           | -                         | 7.40                      | 0.34                         | 220                     |
| rat     | 10           | IV          | 40kD      | 100.85                   | 886                           | -                         | 15.00                     | 0.19                         | 188                     |

Figure 38A

| Group No. | No. Animals | Test Article | Dose    |         | Dose Route | Sample Collection                                   |
|-----------|-------------|--------------|---------|---------|------------|-----------------------------------------------------|
|           |             |              | (mg/kg) | (mL/kg) |            |                                                     |
| 1         | 33F         | ARC187       | 10      | 4       | IV         | t=pre-dose, 0.5, 1, 2, 4, 8, 16, 24, 32, 48, 72 hrs |
| 2         | 33F         | ARC1905      | 10      | 4       | IV         | t=pre-dose, 0.5, 1, 2, 4, 8, 16, 24, 32, 48, 72 hrs |

Figure 38B




Figure 38C

| Noncompartmental PK analysis (NCA)  |           |         |        |
|-------------------------------------|-----------|---------|--------|
| Attribute                           | Unit      | ARC1905 | ARC187 |
| C <sub>max</sub>                    | μM        | 12      | 10     |
| AUC <sub>0-∞</sub>                  | μM·hr     | 88      | 89     |
| MRT <sub>0-∞</sub>                  | hr        | 11      | 11     |
| CL                                  | mL/min·kg | 0.15    | 0.15   |
| V <sub>ss</sub>                     | mL/kg     | 95      | 96     |
| K <sub>10</sub>                     | 1/hr      | 0.151   | 0.121  |
| t <sub>1/2</sub> (K <sub>10</sub> ) | hr        | 5       | 6      |

Figure 39

| Aptamer | Pre | 1hr | 3hr | 6hr |
|---------|-----|-----|-----|-----|
| ARC657  | No  | Yes | Yes | Yes |
| ARC658  | No  | Yes | Yes | Yes |
| ARC187  | No  | Yes | Yes | Yes |

Figure 40

| Group Number | Number of Animals | Test Article         | Dosage Level (mg/kg) | Dose Volume (mL/kg) | Dosing Regimen             | Sample Collection                                                                               |
|--------------|-------------------|----------------------|----------------------|---------------------|----------------------------|-------------------------------------------------------------------------------------------------|
| 1            | 1                 | ARC657<br>20 kDa PEG | 30                   | 3                   | Intravenous bolus on Day 1 | t= pre-dose, 1, 5, 10, 15, and 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 192 hrs |
| 2            | 1                 | ARC658<br>30 kDa PEG | 30                   | 3                   | Intravenous bolus on Day 1 | t= pre-dose, 1, 5, 10, 15, and 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 192 hrs |
| 3            | 1                 | ARC187<br>40 kDa PEG | 30                   | 3                   | Intravenous bolus on Day 1 | t= pre-dose, 1, 5, 10, 15, and 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 192 hrs |

Figure 41

| PK of Anti-CS Aptamer -PEG Conjugates in Cynomolgus Macaque |               |               |               |
|-------------------------------------------------------------|---------------|---------------|---------------|
| Aptamer                                                     | ARC657        | ARC658        | ARC187        |
| PEG Group                                                   | 20 kDa        | 30 kDa        | 40 kDa        |
|                                                             | MEAN          | MEAN          | MEAN          |
| time (hrs)                                                  | Cp ( $\mu$ M) | Cp ( $\mu$ M) | Cp ( $\mu$ M) |
| 0                                                           | 0.00          | 0.00          | 0.00          |
| 0.08                                                        | 16.41         | 21.99         | 18.00         |
| 0.25                                                        | 16.64         | 22.67         | 17.26         |
| 0.5                                                         | 19.38         | 26.16         | 24.17         |
| 1                                                           | 19.36         | 27.08         | 21.79         |
| 4                                                           | 7.73          | 14.16         | 21.69         |
| 8                                                           | 2.03          | 6.02          | 16.68         |
| 12                                                          | 1.10          | 3.04          | 13.11         |
| 24                                                          | 0.36          | 0.95          | 7.24          |
| 48                                                          | 0.15          | 0.42          | 2.30          |
| 72                                                          | 0.07          | 0.25          | 0.96          |
| 96                                                          | 0.03          | 0.23          | 0.54          |
| 192                                                         | 0.01          | 0.04          | 0.14          |

Figure 42

| Species | Dose (mg/kg) | Admin Route | PEG Group | C <sub>max</sub> (ng/ml) | AUC <sub>0-∞</sub> (ng·hr/mL) | t <sub>1/2</sub> (α) (hr) | t <sub>1/2</sub> (β) (hr) | Cl (mL/min/kg) | V <sub>ss</sub> (mL/kg) |
|---------|--------------|-------------|-----------|--------------------------|-------------------------------|---------------------------|---------------------------|----------------|-------------------------|
| primate | 30           | IV          | 20kD      | 293                      | 1191                          | 2.35                      | 31.80                     | 0.41           | 273                     |
| primate | 30           | IV          | 30kD      | 385                      | 2484                          | 3.33                      | 40.08                     | 0.20           | 233                     |
| primate | 30           | IV          | 40kD      | 316                      | 6752                          | 12.38                     | 60.11                     | 0.07           | 141                     |

Figure 43

Figure 43a [sC5b-9] vs time




Figure 43b [sC5b-9] vs [aptamer]




Figure 43c [C5a] vs time




Figure 43d [C5a] vs [aptamer]




Figure 44

| Group Number | Number of Animals | Test Article         | Dosage Level (mg/kg) | Dose Volume (mL/kg) | Dosing Regimen             | Sample Collection                                                                             |
|--------------|-------------------|----------------------|----------------------|---------------------|----------------------------|-----------------------------------------------------------------------------------------------|
| 1            | 4                 | ARC658<br>30 kDa PEG | 30                   | 3                   | Intravenous bolus on Day 1 | pre-dose, 5, 10, 15, and 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144 and 192 hrs |
| 2            | 4                 | ARC187<br>40 kDa PEG | 30                   | 3                   | Intravenous bolus on Day 1 | pre-dose, 5, 10, 15, and 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144 and 192 hrs |

Figure 45




Figure 46

| Species | Dose (mg/kg) | Admin Route | PEG Group | C <sub>max</sub> (μM) | AUC <sub>0-∞</sub> (μg·hr/mL) | t <sub>1/2</sub> (α) (hr) | t <sub>1/2</sub> (β) (hr) | CL <sub>CR</sub> (mL/min/kg) | V <sub>d</sub> (mL/kg) |
|---------|--------------|-------------|-----------|-----------------------|-------------------------------|---------------------------|---------------------------|------------------------------|------------------------|
| primate | 30           | IV          | 30kD      | 519                   | 3059                          | 2.35                      | 30.45                     | 0.16                         | 213                    |
| primate | 30           | IV          | 40kD      | 609                   | 8061                          | 4.48                      | 53.13                     | 0.06                         | 168                    |

Figure 47




Figure 48




Figure 49

| Gr. No. | No. of Animals | Test Article | Dosage Level (mg/kg)                              | Dose Conc. (mg/mL) | Dose Volume (mL/kg)                                   | Dosing Regimen                         | Last Day on Test |
|---------|----------------|--------------|---------------------------------------------------|--------------------|-------------------------------------------------------|----------------------------------------|------------------|
| 1       | 3              | ARC187       | 1 mg/kg IV bolus and 0.0013 mg/kg/min IV infusion | 10                 | 0.1 mL/kg, IV bolus and 0.1872 mL/kg/day, IV infusion | IV bolus and 48 hour infusion on Day 1 | Day 8            |

Figure 50

| Species | Dose (mg/kg) | Admin Route | PEG Group | C <sub>max</sub> (ng/mL) | AUC <sub>0-∞</sub> (ng·hr/mL) | t <sub>1/2</sub> (α) (hr) | t <sub>1/2</sub> (β) (hr) | Cl (mL/min/kg) | W <sub>50</sub> (mL/kg) |
|---------|--------------|-------------|-----------|--------------------------|-------------------------------|---------------------------|---------------------------|----------------|-------------------------|
| primate | 30           | IV          | 40kD      | 610                      | 8061                          | 4.48                      | 53.13                     | 0.06           | 168                     |

Figure 51




Figure 52




Figure 53

| Aptamer | PEG Group | Mol. Wt. (oligo) | Mol. Wt. (total) | $t_{1/2}(\alpha)$ (hr) | $t_{1/2}(\beta)$ (hr) | Total (oligo) Dose for 1.5 $\mu$ M (g) |
|---------|-----------|------------------|------------------|------------------------|-----------------------|----------------------------------------|
| ARC187  | 40 kDa    | 12,703           | 52,703           | 4.48                   | 53.13                 | 0.40                                   |

Figure 54




Figure 55

| treatment                     | ACT (seconds)        |                      |                      |
|-------------------------------|----------------------|----------------------|----------------------|
|                               | Donor 1 <sup>a</sup> | Donor 2 <sup>b</sup> | Donor 3 <sup>b</sup> |
| baseline                      | 133 ± 30             | 145 ± 12             | 138 ± 1              |
| + heparin                     | 842 ± 95             | 519 ± 16             | 450 ± 15             |
| + heparin & ARC187            | nd                   | 618 ± 55             | 492 ± 28             |
| + heparin & protamine         | 160 ± 11             | 155 ± 6              | 159 ± 9              |
| + heparin, protamine & ARC187 | 200 ± 5              | 172 ± 1              | 169 ± 8              |

<sup>a</sup>5 U/mL heparin; <sup>b</sup>4 U/mL heparin; nd, not determined

Figure 56




Figure 57




Figure 58




Figure 59A




Figure 59B

| Serum Species     | ARC1905<br>IC <sub>50</sub> (nM) | ARC127<br>IC <sub>50</sub> (nM) |
|-------------------|----------------------------------|---------------------------------|
| Human             | 0.349<br>±0.0898                 | >10,000<br>NA                   |
| Cynomolgus Monkey | 3.69<br>±0.603                   | >10,000<br>NA                   |
| Rat               | 2700<br>±470                     | ~10,000<br>NA                   |

Figure 60




Figure 61




Figure 62




Figure 63

| Aptamer            | IC <sub>50</sub> (nM) | IC <sub>90</sub> (nM) | IC <sub>99</sub> (nM) |
|--------------------|-----------------------|-----------------------|-----------------------|
| Human              | 196<br>±13.9          | 442<br>±23.2          | 1090<br>±198.0        |
| Cynomolgus Macaque | 536<br>±54.7          | 1810<br>±405.8        | 6900<br>±2600         |
| cyno/human ratio   | 2.73<br>±0.339        | 4.1<br>±0.94          | 6.4<br>±2.65          |

Figure 64




Figure 65




Figure 66

| Donor            | IC <sub>50</sub> (nM) | IC <sub>90</sub> (nM) | IC <sub>99</sub> (nM) |
|------------------|-----------------------|-----------------------|-----------------------|
| Mean of 5 donors | 119                   | 268                   | 694                   |
| SD               | 28.6                  | 39.2                  | 240.9                 |

Figure 67

